Expert recommendations and info about #ChemicalProbes, particularly small molecule inhibitors, and their use in biomedical research and #DrugDiscovery.
Chemical Probes Portal
oxfordglobal.com/discovery-de...
The 10th #ChemicalProbes Hackathon was a great success in Naples!
👥 20 participants
🎓 7 expert reviewers
📝 16 new probe reviews produced
⏰ All in just 4 hours
Thanks to @EUFEPS and SITELF for hosting—and for the real Italian espresso machine at coffee break! ☕🇮🇹
Just a few days until Discovery & Development Europe 2026 in Berlin!
Join us for Paul Workman’s keynote lecture and the Target Identification & Validation Track, co-organised by Susanne Müller-Knapp and supported by ELRIG.
See you there on 15–16 June!
#DrugDiscovery #ChemicalBiology #ELRIG
Heading to Discovery & Development Europe 2026 in Berlin 🇩🇪
Proud that our Portal Director, Paul Workman, will deliver a keynote, and Susanne Müller-Knapp will co-organise the Target Identification & Validation Track (with ELRIG).
📅 15–16 June
#DrugDiscovery #ChemicalBiology #ELRIG
Link 👇
🔗 oxfordglobal.com/discovery-de...
Breakthrough Aurora A PROTAC on the Chemical Probes Portal ⭐⭐⭐⭐
CCT400028 @icr.ac.uk London overcomes the hook effect, delivers >120h stability, is highly selective, and includes a matched inactive control.
Powering paediatric cancer research.
#ChemicalProbes #PROTAC
Read more 👇
Excited about tomorrow!
A full house at @crick.ac.uk for the 9th Chemical Probe Hackathon, with experts from GSK, @icr.ac.uk & TheCrick
working with PhDs & postdocs to review chemical probes and improve research quality.
#ChemicalProbes #ChemBio #OpenScience #Hackathon
A successful PROTAC Hackathon hosted at [email protected]:
• 34 participants
• 24 reviews generated
• 100% reported improved understanding
Organised by the Chemical Probes Portal with academic & industry collaboration.
Next Hackathon: EUFEPS–SITELF 2026 in Naples 🇮🇹
#ChemicalProbes #PROTACs #EUFEPS
Chemical Probes Portal
Pushing traditional boundaries in pharmaceutical science by accelerating the discovery of novel therapeutics
